115 related articles for article (PubMed ID: 8791766)
1. In vitro assessment of various cytochromes P450 and glucuronosyltransferases using the antiarrhythmic propafenone as a probe drug.
Kroemer HK; Botsch S; Heinkele G; Schick M
Methods Enzymol; 1996; 272():99-105. PubMed ID: 8791766
[No Abstract] [Full Text] [Related]
2. Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6.
Uehara S; Murayama N; Yamazaki H; Suemizu H
Xenobiotica; 2019 Nov; 49(11):1323-1331. PubMed ID: 30596462
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of variable antiarrhythmic drug metabolism.
Buchert E; Woosley RL
Pharmacogenetics; 1992 Feb; 2(1):2-11. PubMed ID: 1302039
[TBL] [Abstract][Full Text] [Related]
5. Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450 SUPERSOMES: Evidence for atypical kinetics by CYP2D6 and CYP3A4.
Afshar M; Thormann W
Electrophoresis; 2006 Apr; 27(8):1526-36. PubMed ID: 16609933
[TBL] [Abstract][Full Text] [Related]
6. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
[TBL] [Abstract][Full Text] [Related]
8. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.
Wang JS; Backman JT; Taavitsainen P; Neuvonen PJ; Kivistö KT
Drug Metab Dispos; 2000 Aug; 28(8):959-65. PubMed ID: 10901707
[TBL] [Abstract][Full Text] [Related]
9. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
Kroemer HK; Fischer C; Meese CO; Eichelbaum M
Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
[TBL] [Abstract][Full Text] [Related]
10. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
Olesen OV; Linnet K
Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
Siddoway LA; Thompson KA; McAllister CB; Wang T; Wilkinson GR; Roden DM; Woosley RL
Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342
[TBL] [Abstract][Full Text] [Related]
13. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
[TBL] [Abstract][Full Text] [Related]
14. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4.
De Rienzo F; Fanelli F; Menziani MC; De Benedetti PG
J Comput Aided Mol Des; 2000 Jan; 14(1):93-116. PubMed ID: 10702928
[TBL] [Abstract][Full Text] [Related]
15. Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.
Botsch S; Heinkele G; Meese CO; Eichelbaum M; Kroemer HK
Eur J Clin Pharmacol; 1994; 46(2):133-5. PubMed ID: 8039531
[TBL] [Abstract][Full Text] [Related]
16. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
17. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
Dilger K; Meisel P; Hofmann U; Eichelbaum M
Ther Drug Monit; 2000 Jun; 22(3):366-8. PubMed ID: 10850406
[TBL] [Abstract][Full Text] [Related]
18. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine.
Wang RW; Liu L; Cheng H
Drug Metab Dispos; 1996 Jul; 24(7):786-91. PubMed ID: 8818577
[TBL] [Abstract][Full Text] [Related]
19. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
20. Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro.
Su Y; Liang BQ; Feng YL; Zhan Y; Gu E; Chen X; Dai DP; Hu GX; Cai JP
Can J Physiol Pharmacol; 2016 Aug; 94(8):895-9. PubMed ID: 27203132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
